1. Introduction {#s0005}
===============

Uterine sarcomas are a rare class of mesenchymal tumors that account for 3--7% of uterine malignancies ([@bb0020]). Revised in 2014, the WHO defines diagnostic criteria, by which they are categorized as low-grade or high-grade endometrial stromal sarcomas (ESS), leiomyosarcomas (LMS), or undifferentiated sarcomas (UUS). Most sarcomas demonstrate characteristic features, allowing for straightforward diagnosis based on histology alone. However, some LMS and ESS variants display overlapping histologic features, complicating accurate characterization ([@bb0065], [@bb0060], [@bb0040]). In those cases, immunohistochemical and molecular studies may help determine the true immunohistophenotype of the tumor and guide appropriate treatment. We present an unusual case of a uterine sarcoma with histomorphologic features of a low-grade ESS with an associated high-grade spindle cell sarcoma component, in which immunophenotyping and molecular testing were the defining steps for diagnosis of LMS.

2. Case presentation {#s0010}
====================

An 83-year-old female presented with postmenopausal bleeding and symptomatic anemia. Pelvic examination was remarkable for an enlarged uterus. Transvaginal ultrasonography demonstrated a myomatous uterus with a 7-mm endometrial lining. She underwent hysteroscopy with dilation and curettage. Pathologic evaluation revealed a benign endometrial polyp. Magnetic resonance imaging revealed a 21 × 12 × 18 cm anteverted uterus, containing innumerable typical appearing leiomyomata and a dominant heterogeneous 14 cm mass with internal nodular enhancement, subserosal bulging, and thinning of the overlying myometrium. There was no lymphadenopathy or extra-uterine disease. The patient underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic washings, and omental biopsy. The intraoperative frozen section revealed a spindle cell neoplasm with cytologic atypia, increased mitotic activity, and necrosis, favoring malignancy.

Gross examination revealed an 1850 g uterus distorted by multiple intramural and subserosal nodular masses with a dominant 14 cm intramural mass containing areas of hemorrhage and cystic degeneration. Microscopically, the tumor permeated through the myometrium, with areas of solid destructive growth and extensive necrosis. Lymphovascular space invasion was present ([Fig. 1](#f0005){ref-type="fig"}). Histomorphologically, the tumor exhibited dual populations of neoplastic cells, including solid areas comprised of monotonous small round cells with minimal nuclear atypia, scant cytoplasm, brisk mitotic activity, and delicate vasculature, juxtaposed with spindle cells with marked nuclear pleomorphism and cytologic atypia ([Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}). The latter histologic pattern, along with involvement of the endometrium, raised the possibility of a high-grade/dedifferentiated ESS component. Immunohistochemical studies demonstrated pure smooth muscle immunophenotype in both spindle and round cell components with strong and diffuse immunoreactivity for desmin, smooth muscle actin (SMA), muscle specific antigen (MSA), and h-caldesmon. The CD10 and cyclin D1 immunostains were diffusely negative in both components ([Fig. 4](#f0020){ref-type="fig"}).Fig. 1(H&E, 100 ×): Lymphovascular invasion with the solid tumor nests.Fig. 1Fig. 2(H&E, 100 ×): Dual populations of tumor cells, including spindle cell component with marked nuclear pleomorphism (left), juxtaposed with solid areas of small round monotonous cells with minimal nuclear atypia (right).Fig. 2Fig. 3(H&E, 400 ×): Monotonous round cells (A) and spindle cell population with marked nuclear pleomorphism, occasional multinucleated tumor giant cells, and high mitotic activity (B) (higher magnification).Fig. 3Fig. 4Immunohistochemical studies showing both the small round tumor cells and pleomorphic spindle tumor cells positive for h-caldesmon (A and B, respectively) and negative for CD10 (C and D, respectively).Fig. 4

Molecular studies did not reveal aberrant rearrangements involving *JAZF1*, thus arguing against low-grade ESS. Next generation sequencing of the tumor revealed several genetic alterations, including *ATRX* (S2094), *DNMT3A* (R167fs\*58), *MED12* (G44V), and *TP53* (R181P). Overall, the morphologic and immunophenotypic findings, as well as molecular studies, supported the diagnosis of high-grade uterine leiomyosarcoma with heterogeneous histomorphology.

The patient received adjuvant gemcitabine plus docetaxel, which was discontinued after 3 cycles due to grade 3 infectious and vascular toxicities. She recurred 8 months after completion of chemotherapy and was discharged to hospice care.

3. Discussion {#s0015}
=============

LMS and ESS have vastly different clinical behavior. Though 62--79% of patients with LMS present with stage I disease, recurrences are frequent, ranging 53--71% for those with stage I--II disease ([@bb0020], [@bb0010], [@bb0005], [@bb0030]). In one study, the 5-year overall survival was 51% and 25% for patients with stage I and stage II LMS, respectively ([@bb0010]). Conversely, low-grade ESS is an indolent tumor and 60--76% of cases are confined to the uterus at diagnosis ([@bb0010], [@bb0050]). Recurrences are less frequent, occurring in 1/3 of patients and may occur many years after primary diagnosis. High-grade ESS is believed to behave more like LMS than low-grade ESS. In two small studies, 80% of cases were diagnosed with extra-uterine spread and recurrence rates ranged 70--90% following surgical resection ([@bb0075]).

Defined histologic criteria aid in the classification of uterine sarcomas. Arising from uterine smooth muscle, leiomyosarcoma displays severe nuclear atypia, tumor cell necrosis, and high mitotic activity ([@bb0020]). Endometrial stromal sarcoma arises from the endometrial stroma, infiltrates the myometrium, and demonstrates tumor plugs within lymphovascular spaces. Reminiscent of proliferative-phase endometrial stroma, low-grade ESS characteristically displays bland nuclear features with minimal nuclear atypia, low to variable mitotic rates, and rare necrosis ([@bb0020]). High-grade ESS shows more confluent and destructive myoinfiltration, and demonstrates high-grade nuclear features, higher mitotic rates (\> 10 per 10 HPF), and necrosis. The absence of marked nuclear pleomorphism distinguishes high-grade ESS from UUS ([@bb0040]). Despite well-defined diagnostic criteria, LMS and ESS are notably heterogeneous with varying degrees of cytologic atypia and cellular differentiation, resulting in overlapping histologic features and difficulty with pathologic pattern recognition ([@bb0020], [@bb0065], [@bb0060], [@bb0040]). Furthermore, low-grade and high-grade components may arise simultaneously ([@bb0015]). In these cases, immunohistochemical (IHC) and molecular testing may provide insight into histologic subcategorization ([Table 1](#t0005){ref-type="table"}).Table 1Defining histomorphologic, immunohistochemical, and molecular characteristics of uterine sarcomas ([@bb0035]).Table 1HistomorphologyImmunohistochemistryMolecular testingPositiveNegativeLeiomyosarcomaMarked nuclear atypiaDesminLoss of *ATRX* protein expression (33--39%)High mitotic activityh-CaldesmonTumor cell necrosisSMAMSACD10 (focal/patchy)*PT53* mutation (25--47%)ER/PgR (30--40%)Cytokeratin (epithelioid variant)EMA (epithelioid variant)Low-grade endometrial stromal sarcomaPermeative myoinfiltrationCD10 (diffuse)Desmin*JAZF1*-*JJAZ1* fusion gene (50%)Lymphovascular space invasionSMA (variable)h-CaldesmonMinimal nuclear atypiaMSA (variable)\[*t*(7; 17) (*p*21; *q*15)\]Low to variable mitotic activityER/PgRRare necrosisHigh-grade endometrial stromal sarcomaConfluent permeative and destructive myoinfiltrationCyclinD1CD10YWHAE-FAM22 fusion gene (typically)Lymphovascular space invasionc-KitER/PgRMarked nuclear atypiaSMA (variable)Desmin\[*t*(10; 17) (*q*22; *p*13)\]High mitotic activity (\> 10/10 HPF)MSA (variable)h-CaldesmonTumor cell necrosis

While some immunomarkers are expressed in both LMS and ESS, others are preferentially expressed in one or the other. LMS usually expresses smooth muscle markers, including desmin, h-caldesmon, MSA, and SMA. Focal to patchy immunoreactivity for CD10 may also be seen in LMS. They may also express estrogen and progesterone receptors (ER/PgR) in 30--40% of cases ([@bb0020]). Additionally, epithelioid LMS may express epithelial markers, such as cytokeratin and EMA. Smooth muscle markers may be particularly helpful in distinguishing LMS from ESS. While SMA and MSA may be positive in both, desmin and h-caldesmon are infrequently expressed in ESS ([@bb0020], [@bb0065], [@bb0070]). Additionally, CD10, ER, and PgR, which may be expressed in LMS and low-grade ESS, are typically negative in high-grade ESS, which frequently expresses cyclin D1 ([@bb0060], [@bb0040]).

Molecular testing has led to further advancement in the characterization of these histologically heterogeneous tumors. Low-grade ESS often expresses a *JAZF1* fusion gene ([@bb0060], [@bb0040]). In comparison, authors have reported a *YWHAE*-*FAM22* fusion product in high-grade ESS ([@bb0060], [@bb0040], [@bb0075]). Identification of this fusion gene and recognition of an endometrial stromal sarcoma with permeative myoinfiltration, high grade nuclear features, and high mitotic rates led to the 2014 revision of the WHO classification, which defined a high-grade ESS entity.

Appropriate classification of uterine sarcomas is essential for accurate selection of adjuvant therapy. The mainstay of treatment for LMS and ESS is surgical resection with total abdominal hysterectomy and bilateral salpingo-oophorectomy with or without lymph node sampling. The role of adjuvant therapy following surgical resection of LMS is controversial and generally reserved for advanced or recurrent disease. Conversely, adjuvant hormonal therapy may be used in cases of advanced or recurrent low-grade ESS. Limited treatment data is available for high-grade ESS. However, NCCN guidelines recommend similar management strategies as with LMS. Appropriate use of adjuvant therapy in uterine sarcomas remains an area of active research, with clinical trials available at many sites.

In this unusual case, tumor histomorphology demonstrated features of low-grade ESS and high-grade spindle cell sarcoma. Though high-grade ESS may be seen arising in preexisting low-grade ESS, to the best of our knowledge, no reported cases of LMS or UUS arising in a background of low-grade ESS have been reported (search engine [PubMed.gov](http://PubMed.gov){#ir0005}; search terms uterine sarcoma, endometrial stromal sarcoma, leiomyosarcoma). Based on histology alone, this tumor was best considered a high-grade ESS evolving from low-grade ESS. However, IHC revealed smooth muscle immunophenotype in both low-grade and high-grade components. The absence of the *JAZF1* fusion protein further argued against the diagnosis of ESS, and supported a smooth muscle derivation of this sarcoma. Integration of histomorphologic and immunohistochemical findings with the results of molecular testing confirmed a definitive diagnosis of high-grade LMS with heterogeneous morphology, upon which further specific therapeutic options were recommended.

Next generation sequencing identified several genetic alterations, including *ATRX* (S2094), *DNMT3A* (R167fs\*58), *MED12* (G44V), and *TP53* (R181P). Loss of *ATRX* protein expression has been reported in 33--39% of leiomyosarcomas and is associated with poor prognosis in non-uterine LMS ([@bb0045]). *DNMT3A* mutations have not been reported in LMS or other soft tissue sarcomas. A mutational hotspot in exon 2 of *MED12* is altered in most uterine leiomyomata ([@bb0055]). *TP53* mutations have been reported in 25--47% of uterine leiomyosarcomas and one study reported allelic loss of *TP53* locus in 75% of cases ([@bb0035], [@bb0025]).

In summary, a small subset of uterine sarcomas may exhibit ambiguous histologic features. In such cases, the use of ancillary studies may accurately subclassify uterine sarcomas and allow for assignment of appropriate adjuvant therapy. As drug development progresses and targeted therapy becomes available, the role of molecular testing in rare and unusual tumors is becoming crucial. Finally, our ability to accurately subclassify histologically ambiguous tumors may positively impact the integrity of clinical trial enrollment.
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